Indonesia Retailers - Limited surprises as expected
2Q24 review: ERAA upbeat and ACES downbeat were the only surprises Overall results were largely in line
Alfamidi delivered a solid performance in 1Q25, recording +20% y-y earnings growth, achieving 29% of our 2025F earnings forecast. Excluding losses from the Lawson (unlisted) operation, Alfamidi's earnings rose even more strongly, up +28% y-y (Fig. 2). The slight y-y decline in gross profit margin (GPM) appears to have been driven by the timing of the Lebaran holiday, during which promotional activities typically increase. Losses from the Lawson business widened to IDR57bn (+42% y-y), or IDR40bn on an adjusted basis, reflecting Alfamidi's 70% ownership (Fig. 3). Opex as a percentage of sales fell by 60bp y-y, mainly due to a 40bp reduction in salary costs. We believe this was driven by a reallocation of employees from closed Lawson stores, as the total number of employees remained flat y-y despite the addition of ~200 new Alfamidi stores last year.
What to see beyond 1Q25
We believe that Alfamidi is similar to Alfamart (AMRT IJ, Buy), as they are both selling basic daily necessities to the consumers. Hence, the defensiveness of its business model should be able to help it withstand a tougher macro environment. Moreover, Alfamidi is positioned for stronger growth than AMRT, in our view, due to its higher ex-Java sales mix of 52% (vs AMRT's 32%), benefiting from favorable soft commodity prices that enhance consumer spending power in those regions. We believe the upcoming transfer of the Lawson business to AMRT, scheduled for later in May, should further support Alfamidi’s earnings. Lawson’s losses, which have weighed on MIDI’s profitability over the past year, will be removed from the books. We estimate this could provide a ~5% boost to MIDI’s earnings relative to our forecasts (Fig. 4).
Maintain Buy with TP of IDR420
Our TP is based on a 20.7x 2025F P/E, implying a 25% discount to our 27.6x target P/E for AMRT. While limited liquidity has always been investors’ pushback, we believe the strong 1Q25 results, the divestment of Lawson, and the company’s resilient business model could serve as meaningful positive catalysts for the stock. Key downside risks include sustained weakness in consumer purchasing power. Currently, MIDI trades at a 19x 2025F P/E.
| MIDI IJ | QoQ | YoY | 3M25/ | 3M25/ | |||
| Profit and loss statement (IDRbn) | 1Q24 | 4Q24 | 1Q25 | (%) | (%) | Verdhana | Consensus |
| Revenue | 4,794 | 5,202 | 5,525 | 6.2 | 15.3 | 26.4% | 25.6% |
| COGS | 3,525 | 3,876 | 4,074 | 5.1 | 15.6 | ||
| Gross profit | 1,268 | 1,326 | 1,451 | 9.4 | 14.4 | ||
| EBIT (Incl. fee based) | 173 | 79 | 217 | 175.7 | 25.8 | 29.6% | 28.2% |
| Net interest income/(expense) | (12) | (13) | (11) | (14.8) | (10.3) | ||
| R&D income | 10 | - | - | n.a. | (100.0) | ||
| Other income (expense) | 56 | 52 | 48 | (7.6) | (14.2) | ||
| Pre-tax profit | 197 | 97 | 234 | 140.5 | 18.9 | ||
| Net profit | 161 | 80 | 194 | 143.3 | 20.1 | 28.8% | 27.6% |
| Gross margin (%) | 26.5 | 25.5 | 26.3 | ||||
| EBIT margin (%) | 3.6 | 1.5 | 3.9 | ||||
| Pre-tax margin (%) | 4.1 | 1.9 | 4.2 | ||||
| Net margin (%) | 3.4 | 1.5 | 3.5 | ||||
| Balance sheet (IDRbn) | Mar-24 | Dec-24 | Dec-24 | ||||
| Cash and equivalents | 412 | 378 | 769 | ||||
| Total assets | 8,510 | 8,733 | 9,536 | ||||
| Total liabilities | 4,418 | 4,442 | 5,072 | ||||
| Interest bearing liabilities | 150 | - | - | ||||
| Equity | 4,092 | 4,291 | 4,464 | ||||
| ROA (%) | 7.6 | 3.6 | 8.1 | ||||
| ROE (%) | 15.8 | 7.4 | 17.3 | ||||
| Gearing (%) | 3.7 | - | - | ||||
| Net gearing (%) | n.c. | n.c. | n.c. |
| MIDI 2025 (IDRbn) | Before | After | Remarks |
| Profit before tax (a) | 807 | 877 | Assume 100 Lawson closures in 1H (IDR70bn) |
| Tax expense (c) | - 178 | - 193 | |
| Minority interest (b) | - 42 | - 21 | |
| Net profit after tax (a+b-c) | 671 | 705 | 5% higher profit |
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
| Rating Remains | Buy |
| Target price Remains | IDR 420 |
| Closing price 30 April 2025 | IDR 390 |
Jody Wijaya (jody.wijaya@verdhana.id)
Sandy Ham (sandy.ham@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)
saya
2Q24 review: ERAA upbeat and ACES downbeat were the only surprises Overall results were largely in line
2Q24 result miss due to lower GPM; but it should be bottom GPM for the year
JA~DI, an Indonesian acronym for "Jajan di Alfamidi" (meaning “Snacking at Alfamidi”), is a pilot
Aspirasi Hidup Indonesia (ACES IJ, Neutral) — We estimate a robust 11%/13% y-y increase in both sales/net prof
Overall, the results were in line with our expectations, as we believe that 2Q24 marked the lowest margin poin
While Mitra Adiperkasa’s (MAPI) 3Q24 y-y sales growth remained strong at +17%,